Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPT NASDAQ:CYTK NASDAQ:PCVX NASDAQ:PRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$13.33-1.5%$14.17$8.50▼$20.76$2.13B2.161.95 million shs286,502 shsCYTKCytokinetics$74.29-0.4%$64.73$29.31▼$80.20$9.24B0.382.22 million shs745,171 shsPCVXVaxcyte$53.61-0.7%$58.09$28.64▼$65.00$7.74B1.31.39 million shs412,537 shsPRAXPraxis Precision Medicines$324.43-2.2%$317.26$35.21▼$356.00$9.01B2.76459,046 shs52,920 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-1.96%-5.12%+5.86%-13.43%+49.94%CYTKCytokinetics-3.06%+17.70%+14.69%+14.97%+135.28%PCVXVaxcyte+1.85%-5.16%-11.32%-1.80%+73.27%PRAXPraxis Precision Medicines+0.54%+2.35%+4.96%+3.54%+765.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$13.33-1.5%$14.17$8.50▼$20.76$2.13B2.161.95 million shs286,502 shsCYTKCytokinetics$74.29-0.4%$64.73$29.31▼$80.20$9.24B0.382.22 million shs745,171 shsPCVXVaxcyte$53.61-0.7%$58.09$28.64▼$65.00$7.74B1.31.39 million shs412,537 shsPRAXPraxis Precision Medicines$324.43-2.2%$317.26$35.21▼$356.00$9.01B2.76459,046 shs52,920 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-1.96%-5.12%+5.86%-13.43%+49.94%CYTKCytokinetics-3.06%+17.70%+14.69%+14.97%+135.28%PCVXVaxcyte+1.85%-5.16%-11.32%-1.80%+73.27%PRAXPraxis Precision Medicines+0.54%+2.35%+4.96%+3.54%+765.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.63Moderate Buy$20.0049.99% UpsideCYTKCytokinetics 2.82Moderate Buy$98.5532.66% UpsidePCVXVaxcyte 2.63Moderate Buy$86.0060.43% UpsidePRAXPraxis Precision Medicines 3.00Buy$591.8382.42% UpsideCurrent Analyst Ratings BreakdownLatest ADPT, PRAX, PCVX, and CYTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026CYTKCytokinetics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$92.00 ➝ $97.005/11/2026CYTKCytokinetics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$136.00 ➝ $140.005/8/2026PRAXPraxis Precision Medicines Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$420.005/8/2026PRAXPraxis Precision Medicines WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderperform$130.00 ➝ $166.005/8/2026PRAXPraxis Precision Medicines BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$843.005/7/2026PRAXPraxis Precision Medicines Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/7/2026CYTKCytokinetics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$95.00 ➝ $105.005/6/2026CYTKCytokinetics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$90.00 ➝ $103.005/6/2026CYTKCytokinetics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$119.005/6/2026CYTKCytokinetics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$101.00 ➝ $119.005/6/2026ADPTAdaptive Biotechnologies TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $21.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$276.98M7.70N/AN/A$1.47 per share9.07CYTKCytokinetics$88.04M104.99N/AN/A($5.39) per share-13.78PCVXVaxcyteN/AN/AN/AN/A$20.51 per shareN/APRAXPraxis Precision Medicines$8.55M1,057.90N/AN/A$34.85 per share9.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$59.50M-$0.33N/AN/AN/A-16.82%-40.06%-16.64%N/ACYTKCytokinetics-$784.96M-$6.84N/AN/AN/A-784.02%N/A-52.86%N/APCVXVaxcyte-$766.63M-$6.88N/AN/AN/AN/A-32.51%-29.51%N/APRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-60.25%-54.81%N/ALatest ADPT, PRAX, PCVX, and CYTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/6/2026Q1 2026PCVXVaxcyte-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/A5/5/2026Q1 2026ADPTAdaptive Biotechnologies-$0.16-$0.13+$0.03-$0.13$61.03 million$70.87 million5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million2/24/2026Q4 2025CYTKCytokinetics-$1.48-$1.50-$0.02-$1.50$8.02 million$17.76 million2/24/2026Q4 2025PCVXVaxcyte-$1.46-$1.80-$0.34-$1.80$18.75 millionN/A2/19/2026Q4 2025PRAXPraxis Precision Medicines-$3.00-$3.50-$0.50-$3.50$0.26 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A3.353.22CYTKCytokineticsN/A4.214.21PCVXVaxcyteN/A7.497.49PRAXPraxis Precision MedicinesN/A10.2210.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%CYTKCytokineticsN/APCVXVaxcyte96.78%PRAXPraxis Precision Medicines67.84%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies5.70%CYTKCytokinetics2.60%PCVXVaxcyte3.10%PRAXPraxis Precision Medicines2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790160.04 million150.92 millionOptionableCYTKCytokinetics250124.43 million121.20 millionOptionablePCVXVaxcyte160144.40 million139.92 millionOptionablePRAXPraxis Precision Medicines11027.88 million27.13 millionOptionableADPT, PRAX, PCVX, and CYTK HeadlinesRecent News About These CompaniesHC Wainwright Issues Pessimistic Outlook for PRAX Earnings4 hours ago | marketbeat.comLifesci Capital Brokers Lower Earnings Estimates for PRAX4 hours ago | marketbeat.comPraxis Precision Medicines Maps High-Stakes Launch PathMay 11 at 9:11 PM | tipranks.comWedbush Maintained an Underperform Rating on Praxis Precision Medicines, Inc. (PRAX)May 11 at 8:31 PM | insidermonkey.comUBS Group AG Sells 7,612 Shares of Praxis Precision Medicines, Inc. $PRAXMay 11 at 7:09 AM | marketbeat.comState of New Jersey Common Pension Fund D Acquires New Position in Praxis Precision Medicines, Inc. $PRAXMay 11 at 5:00 AM | marketbeat.comHC Wainwright Has Negative Outlook of PRAX FY2030 EarningsMay 11 at 1:56 AM | americanbankingnews.comResearch Analysts Issue Forecasts for PRAX FY2030 EarningsMay 11 at 1:54 AM | marketbeat.comBTIG Research Reiterates "Buy" Rating for Praxis Precision Medicines (NASDAQ:PRAX)May 10 at 4:19 AM | americanbankingnews.comPraxis Precision Medicines (NASDAQ:PRAX) Stock Price Expected to Rise, Wedbush Analyst SaysMay 10 at 4:18 AM | americanbankingnews.comPraxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call TranscriptMay 9 at 2:04 PM | seekingalpha.comAnalysts Are Bullish on These Healthcare Stocks: Praxis Precision Medicines (PRAX), NewAmsterdam Pharma Company (NAMS)May 8, 2026 | theglobeandmail.comPraxis Precision Medicines Q1 Earnings Call HighlightsMay 8, 2026 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $166.00May 8, 2026 | marketbeat.comBTIG Research Reaffirms Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX)May 8, 2026 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Issues Earnings ResultsMay 7, 2026 | marketbeat.comPraxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | finanznachrichten.dePraxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comStrs Ohio Invests $943,000 in Praxis Precision Medicines, Inc. $PRAXMay 7, 2026 | marketbeat.comPraxis earnings up next as biotech nears commercial transformationMay 6, 2026 | investing.comPraxis Precision Medicines, Inc. $PRAX Shares Bought by Vanguard Group Inc.May 6, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADPT, PRAX, PCVX, and CYTK Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$13.33 -0.21 (-1.52%) As of 11:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Cytokinetics NASDAQ:CYTK$74.28 -0.28 (-0.37%) As of 11:53 AM Eastern This is a fair market value price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Vaxcyte NASDAQ:PCVX$53.60 -0.39 (-0.71%) As of 11:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Praxis Precision Medicines NASDAQ:PRAX$324.43 -7.38 (-2.22%) As of 11:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
